Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Scientific Reports Publishes International Stem Cell Corp. (ISCO) Technology For Deriving Neuronal Cell

|Includes: International Stem Cell Corp. (ISCO)

International Stem Cell Corp., a biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSC), this morning told investors that its breakthrough method of deriving neuronal cells for the treatment of Parkinson's disease has been published in Scientific Reports, a primary research publication from the publishers of Nature Publishing Group.

Parkinson's disease (PD) is a common neurodegenerative disorder caused by a progressive loss of dopamine-producing neurons resulting in gradual dysfunction of the motor system. Pharmacological treatments are useful in the relatively early stage of the disease, but the continuous use of pro-dopaminergic medication eventually becomes ineffective and can worsen some of the motor symptoms. ISCO is developing a treatment for PD based on replacing the lost neurons with new neuronal cells derived from human parthenogenetic stem cells. To this end ISCO has developed a sophisticated and efficient manufacturing process for neuronal cells which has now been published in the peer-reviewed journal Scientific Reports.

The paper describes the technology, developed by ISCO's R&D team, for producing highly pure populations of GMP-grade neuronal cells suitable for pre-clinical studies and clinical trials. The neuronal cells created using this approach are further characterized using a number of analytical methods and shown to function in a similar manner to adult cells. Moreover, neuronal cells produced using this new method, express greater levels of dopamine, the neurotransmitter central to PD, than previously reported approaches. Furthermore, these hpSC-derived neuronal cells are cryopreservable and can be stored frozen, and provides a practical route to creating neurons of sufficient quality to be used to treat Parkinson's disease patients.

"It is important that our research is reviewed and validated by the scientific community and being able to publish in a Nature-branded, journal provides confirmation of the quality of ISCO's scientific research," stated Dr. Andrey Semechkin, CEO and Co-Chairman.

For more information, visit

Please see disclaimer on the QualityStocks website: